Browse Articles
Discover research articles across all indexed journals
Association between rheumatoid arthritis and interstitial lung disease and impact of serologic status: a large-scale longitudinal study
Targeting the soluble epoxide hydrolase (sEH) enzyme to relieve painful docetaxel-induced peripheral neuropathy.
126 Background: Docetaxel is an important chemotherapeutic agent used for the treatment of several cancers, including metastatic prostate cancer. Unfortunately, it shares the side effect profile of other taxanes, including causing painful chemotherapy-induced peripheral neuropathy (CIPN). The pain of CIPN is notoriously difficult to treat, can lead to discontinuation of life-prolonging cancer treatments and can become a debilitating, chronic condition. Notably, African American (AA) cancer patients have increased (2-3-fold) risk and increased severity of CIPN. The enzyme soluble epoxide hydrolase (sEH) functions as a master regulator of inflammation, by converting epoxy fatty acids (EpFAs), which are polyunsaturated fatty acid (PUFA) derivatives with inflammation-resolving, analgesic and anti-cancer properties, into corresponding inactive or pro-inflammatory diols. As sEH inhibition has demonstrated efficacy in several models of neuropathy, here we assessed its potential to relieve and/or prevent docetaxel-induced CIPN specifically. Methods: We established a model of docetaxel-induced painful neuropathy in male Sprague Dawley rats, by administering 3 doses of docetaxel (10 mg/kg intraperitoneally, once weekly, for 3 doses). We tested the efficacy of the small molecule sEH inhibitor EC5026 (EicOsis, Inc, Davis, CA) both (1) as a single dose administered via oral gavage and (2) via chronic administration (1 mg/kg/day) in the drinking water started 1 week prior to and continuing during the period of docetaxel treatments. To examine the analgesic efficacy of EC5026, the rats were assessed for responses in nociceptive (von Frey assay and cold plate assay) and functional (open field test) behavior assays. Tail vein blood was sampled, and the blood concentration of docetaxel (measured by mass spectrometry) was compared between vehicle-treated and EC5026-treated cohorts. Results: Oral dosing of the sEH inhibitor EC5026 dose-dependently relieved docetaxel-induced painful neuropathy. Additionally, chronic treatment with EC5026 via the drinking water blocked both tactile allodynia and cold sensitivity compared to vehicle-treated rats. The open field assay revealed that EC5026 has no negative effect on motor skills. Moreover, EC5026 did not affect the blood levels of docetaxel in rats. Conclusions: sEH is a novel target for achieving pain relief in our CIPN model. Our results indicate robust response to therapeutic treatment of the CIPN model and additionally improved outcomes with prophylactic administration of the sEH inhibitor EC5026 in docetaxel-induced painful CIPN, without effect of EC5026 on animal motor skills or docetaxel pharmacokinetics.
Influence of MRIs performed in a 6-week interval on the histopathological detection of prostate cancer with different PIRADS classifications: A real-world data analysis.
334 Background: In the early phases of MRI-guided prostate biopsies, it was often necessary to perform an additional in-house multiparametric MRI after an external MRI to accurately assess lesions for biopsy. This study aims to evaluate the consistency of lesion identification and the associated clinical and histological outcomes at a high-volume tertiary care center performing over 500 biopsies annually. Methods: This analysis included real-world data from 111 patients treated between 2018 and 2022. Each patient underwent two multiparametric MRI scans of the prostate at different institutions, with a median interval of 42 days [32–52] between scans. An MRI-fused biopsy followed 7 days [4–10] after the second MRI. Data were analyzed using the Chi-square test. Results: The PIRADS scores for index lesions on the in-house MRI were as follows: PIRADS V in 33.3% (n=37), PIRADS IV in 49.5% (n=55), PIRADS III in 12.6% (n=14), and PIRADS II in 4.5% (n=5) (Table 1). Most lesions were located in the peripheral zone of the prostate (68.8%, n=75). Cancer detection rates for randomized and/or targeted biopsies were 91.9% (n=34) for PIRADS V, 65.5% (n=36) for PIRADS IV, 21.4% (n=3) for PIRADS III, and 20% (n=1) for PIRADS II. Clinically significant prostate cancer (ISUP > 1) was detected in 91.9% (n=34) of PIRADS V, 60% (n=33) of PIRADS IV, and 21.4% (n=3) of PIRADS III lesions. Overall, malignant histology was found in 64.9% (n=72) of targeted lesions and 59.5% (n=66) of randomized biopsies. A median of 7 [5.5–8.5] biopsies were taken per lesion, with an additional 13 [11–15] randomized biopsies. In the initial external MRI, 18% (n=20) of patients were assigned a higher PIRADS category, while 10.8% (n=12) were had a lower score (p<0.001). The biopsy plan was adjusted for 57 patients (51.4%) based on the findings of the second MRI. However, given the cancer detection rates in both targeted and randomized biopsies, it is likely that all cancers would have been detected regardless of these adjustments. Conclusions: Although PIRADS classifications varied slightly between the two MRI scans performed six weeks apart, and biopsy plans were adjusted in about half of the cases, all cancers would likely have been identified. The six-week interval between MRI scans does not appear to significantly affect biopsy accuracy. PIRADS classification comparison of internal and external MRI. External MRI PIRADS II PIRADS III PIRADS IV PIRADS V All Internal MRI PIRADS II 0 40% (2) 40% (2) 20% (1) 5 PIRADS III 0 28.6% (4) 57.1% (8) 14.3% (2) 14 PIRADS IV 0 9.1% (5) 81.8% (45) 9.1% (5) 55 PIRADS V 0 2.7% (1) 16.2% (6) 81.1% (30) 37 All 0 12 60 39
Intra-patient comparison of urinary radioactivity after <sup>18</sup> F-piflufolastat and <sup>18</sup> F-flotufolastat PET in men with low PSA biochemical recurrence of prostate cancer who have had radical prostatectomy.
TPS272 Background: Prostate-specific membrane antigen (PSMA)-targeting positron emission tomography (PET) radiopharmaceuticals enable early detection of metastatic and recurrent prostate cancer (PCa). High urinary radioactivity of some PSMA-PET agents can affect interpretation of scans in the pelvic region (prostate/prostate bed [PB]; pelvic lymph nodes [PLN]). 18 F-Piflufolastat and 18 F-flotufolastat are FDA-approved, mainly renally cleared, diagnostic PSMA-PET agents; data suggest 18 F-flotufolastat has lower urinary radioactivity than 18 F-piflufolastat, but no clinical differences have been confirmed by head-to-head intra-patient studies. The present study will directly compare the urinary radioactivity of 18 F-piflufolastat with 18 F-flotufolastat in men with low prostate-specific antigen (PSA) biochemical recurrence (BCR) of PCa after radical prostatectomy (RP). Methods: This multicenter, prospective, intra-patient comparator study will include men (≥ 18 years old) with low PSA (≤ 0.5 ng/mL) BCR of PCa who have had RP ≥ 6 months before enrollment (with undetectable PSA post surgery) and are due to have routine 18 F-piflufolastat PET. Men who have had prior 18 F-piflufolastat PET or salvage therapy, or with conditions affecting urinary output, will be excluded. Eligible patients will undergo 18 F-piflufolastat PET followed by 18 F-flotufolastat PET ≥ 24 hours but ≤ 10 days later. No diuretic will be administered for scanning purposes. Each radiopharmaceutical will be administered as a single intravenous bolus per approved US prescribing information (USPI). Scanning (with the same scanner for both scans) will start 50–90 minutes post injection of 18 F-piflufolastat and 50–70 minutes post injection of 18 F-flotufolastat. Each patient will be their own control. The primary endpoint will be difference in mean standardized uptake value (SUV mean ) between 18 F-piflufolastat and 18 F-flotufolastat as assessed in volumes of interest drawn on the urinary bladder. Secondary endpoints for both agents will include detection rates: at the patient level (overall; by baseline PSA); for local recurrences in PB subregions; and for PLN lesions. For secondary endpoints, PET scans will be interpreted per product-specific USPI by 2 specially trained, blinded, central readers (a third reader will adjudicate disagreements). Safety will be monitored until 24 hours after the second scan. Around 60 men will be screened and ≥ 52 with evaluable PET scans for both agents will be included in the primary analysis. The primary endpoint will be assessed for normality and a difference in SUV mean will be tested using 2-sided paired tests (Wilcoxon signed-rank test [non-normal]; t-test [normal]). All further endpoints, including safety, will be summarized descriptively. The trial has been open for enrollment since 10/24. Clinical trial information: NCT06604442 .
Assessment of public awareness and perspectives towards adverse drug reaction reporting system in Karachi, Pakistan
Background Public involvement in reporting adverse drug reactions (ADRs) generates a broader database on drug safety. Underreporting remains a hindrance to implementing an effective pharmacovigilance system that ultimately affects public health. Hence, it is critical to appraise the public’s awareness of ADR reporting and pharmacovigilance to address the gaps for the enhancement of ADR reporting rate. Objectives The current study explored public knowledge and attitudes toward ADR reporting in Karachi, Pakistan. Methods A quantitative cross-sectional study was conducted from 3rd Jan 2022 to 30th Nov 2022 using a forty-item questionnaire to evaluate public insights regarding the ADR and its reporting. Descriptive analysis was executed to determine frequencies and percentages for the respondents’ baseline characteristics and the responses toward ADR reporting. The chi-square test (χ2) was applied to determine the association between the dependent and independent variables considering a p-value < 0.05 as statistically significant. Results The response rate of the present study was 78.3%. More than 80% of the respondents deemed that ADR occurs only with high doses of medicines and over-the-counter medications do not cause any ADR. More than 75% of the respondents did not know that the ADR reporting form is available on the Drug Regulatory Authority of Pakistan (DRAP) website; the response varied significantly with the education (p = 0.002) and social status (p = 0.0001) of the respondents. More than 50% of the participants refused to ever report an ADR to health professionals. Physicians (n = 364; 47.7%) and pharmacists (n = 253; 33.1%) were the respondents’ professed most reliable sources to whom ADR can be reported; responses varied significantly with their education (p = 0.003) and age (p = 0.001). Conclusions The study has provided insight into the challenges and gaps needed to improve ADR reporting in Pakistan. The outcomes revealed that the public is aware of the benefits of reporting ADRs; however, they do not realize their role and the potentially significant impact on the healthcare system by contributing to ADR reporting. Therefore, it is a need of time to educate the public on the value of reporting ADRs and implement user-friendly and accessible ADR reporting systems in patient care areas to facilitate easier reporting.
Author Correction: Memory reactivation generates new, adaptive behaviours that reach beyond direct experience
Survival outcomes of de novo mHSPC based on hemoglobin A1C and ARPI therapy.
139 Background: While there has been no prospective studies, enzalutamide (enza) has better overall survival, fewer adverse events, risk of progression, and PSA response compared to the abiraterone (abi) in real-world treatment of metastatic prostate cancer with androgen receptor pathway inhibitors (ARPI)s. Diabetes (T2DM) is a major comorbidity in elderly patients, with worse glycemic control as a risk factor for and worse cancer outcomes. Studies analyzing the role of ARPIs in patients with diabetes have found enza associated with longer survival, less frequent acute hospitalizations, and likelihood of developing T2DM, compared to abi. However, there is little data in hormone sensitive population (mHSPC), where ARPIs are most commonly used. This study analyzed the association between use of APRI treatment and survival in patients with controlled versus uncontrolled diabetes based off hemoglobin A1C (hgbA1C). Methods: 1591 Patients with de novo mHSPC diagnosed between 2017-2023, treated with abiraterone or enzalutamide with 4 months of ADT, and hgbA1C within 1 year prior and up to 3 months after cancer diagnosis were retrospectively identified. Additional variables included age, BMI, base-line prostate specific antigen at diagnosis, Charlson Comorbidity Index score (CCI). Kaplan-Meier method was used to compare overall survival months based on hgbA1C and diabetes diagnosis. Cox proportional hazard modeling was performed to assess the relationship when adjusting for confounding variables. Results: The cohort included 1591 patients with de novo mHSPC, 1,196 who received abiraterone and 395 who received enzalutamide. Veterans treated with enza were older (mean 74.4 years vs. 73.0, p<0.001) with higher CCI (mean 2.6 vs. 2.0, p<0.001). Veterans with hgbA1C>6.5 were more likely to be prescribed enzalutamide (31.1% vs. 21.6%, p<0.001). Veterans with hgbA1C<6.5 had significantly longer survival compared to veterans with hgbA1C>6.5 (41.5 vs. 33.3 months, HR 0.79 95%, CI 0.68-0.91). Patients treated with abiraterone had a significant difference in survival based on hgbA1C (41.5 vs. 31.1, HR 0.79, CI 0.67-0.93). In patients treated with enzalutamide, there was no significant difference in survival (40.7 vs. 38.0, HR 0.80 95%, CI 0.60-1.07). A1C remained predictive of mortality (HR 1.27, 95CI 1.10-1.48) when controlled for PSA, BMI, ARPI, and age. Conclusions: In veterans with mHSPC who are treated with abiraterone, elevated hgbA1C is associated with shorter survival. No differences were seen in veterans treated with enzalutamide; however, these analyses may be underpowered. These results may help in treatment selection and support glycemic control when treating patients with mHSPC and comorbidities. ARPI A1C Median OS (months) HR 95 CI Abiraterone <6.5 41.5 0.79 0.67-0.93 6.5+ 31.1 overall 39.2 Enzalutamide <6.5 40.7 0.80 0.60-1.07 6.5+ 38.0 overall 39.4
Biomarker testing patterns among patients newly diagnosed with prostate cancer in a community oncology network.
229 Background: Prostate cancer guidelines recommend that clinicians order biomarker testing for patients with metastatic prostate cancer. In addition, testing is recommended to determine patients’ eligibility for clinical trials and to identify potential actionable mutations that can inform appropriate treatment strategies. The aim of this study was to evaluate biomarker testing patterns among patients newly diagnosed with prostate cancer who received care in a large community oncology provider network. Methods: A retrospective database analysis, using several sources that include iKnowMed (EMR), Ellkay CareEvolve (Genetic HL7 interface), and the Molecular Data Warehouse and covers approximately 1.7 million distinct patients, was conducted on patients newly diagnosed with prostate cancer between Jan 1, 2018, and Jun 30, 2022, and receiving care in a large oncology network in West South-Central United States. Baseline demographics and clinical characteristics were analyzed descriptively and the proportion of patients who received biomarker testing was determined. Results: Data on 18,743 patients with prostate cancer (mean age at diagnosis, 71 years; 46% White, 13% Hispanic, 7% Black, 1% Asian, 33% other/unknown) were abstracted. The proportion of patients who received biomarker testing was 14% overall and 23% among those with Stage IV disease. Of all biomarker tests performed, roughly 6% was single gene testing, 49% was broad panel testing, 25% was both single gene testing with broad panel testing, and approximately 20% of the tests were unknown. The average time from first biomarker testing to disease diagnosis was approximately 5 months. Less than 10% of the patients who tested positive with an actionable mutation received targeted therapy. Hormone therapy (32%) was the most common treatment received, followed by supportive care (7%). Conclusions: These findings provide insights into the frequency of biomarker testing among patients newly diagnosed with prostate cancer who receive care in a large community practice setting. Advancement in targeted therapies is predicated on improved testing rates, and this study suggests opportunities exist for interventions and increased education among healthcare providers based on observed time to testing and the rate of testing. Biomarker testing patterns in patients with prostate cancer. Parameter Patients with prostate cancer(N=18,743) Received biomarker testing All patients, n (%) 2,585 (14) Patients with metastatic Stage IV disease, n/n (%) 941/4,168 (23) Received targeted therapy after positive biomarker testing indicating actionable mutation, n/n (%) 36/450 (8) Mean (standard deviation) days from ordering biomarker test to: Disease diagnosis 156 (545) Receiving results 52 (213) Treatment initiation 113 (525)
Improving health related quality of life (HRQoL) assessment and immune related adverse event (irAE) classification with novel tools in renal cancer.
525 Background: HRQoL tools and adverse event criteria were designed around outdated therapies and require re-evaluation in the era of immune checkpoint inhibitors (ICI). Attempts have been made to create a novel HRQoL tool (Bergerot et al) but this has not been validated in prospective data sets. To our knowledge no attempts have been made to re-evaluate current toxicity grading systems. Data from PRISM, a randomized ph2 trial which explored scheduling of 1 st line ipilimumab/nivolumab in advanced renal cell carcinoma (RCC), was used to validate these novel tools. Methods: HRQoL (EORTC QLQ-C30 & FKSI-19) and irAE data graded using common terminology criteria for adverse events (CTCAE) were analysed in treatment naïve patients with advanced RCC recruited to PRISM. Patients were randomised 2:1 to 4 doses of ipilimumab 12-weekly (modified) or 3-weekly (standard) in combination with nivolumab. The novel QoL tool, created with patient engagement and expert input, was prospectively tested and compared with scores for FKSI-19 (0-76) and QLQ-C30 (0-100). irAEs (graded 1-5 CTCAEv5) were reclassified by patient advocates into 3 groups; life changing (LC), significant (S), non-significant (NS). These were further classified into short term (ST) or long term (LT). Results: In PRISM 192 patients were randomised 2:1 (128 modified, 64 standard schedule). HRQoL scores were available for 157 patients at baseline, week 13 and 25. Baseline scores were comparable across all 3 (QLQ-C30, FKSI-19, novel tool) tools. IMDC good risk patients had higher QOL scores at baseline across all three questionnaires compared to intermediate/poor risk (FSKI 64 vs 58, QLQC-30 86 vs 77, novel tool 59 vs 53, p <0.05). Only the novel tool showed significantly improved QoL (57 v 51, p >0.05) at 13 weeks. There was no correlation between occurrence of grade 3/4 irAEs and reduction in QOL as reported in PRISM. QoL scores in patients with progressive disease were worse across all tools (FSKI 52.3 v 58.9, QLQC-30 60.3 v 75.2, novel tool 48 v 56.4, p <0.02). 1158 irAEs were reported and reclassified. All grade 1 irAEs were deemed NS. The table shows the frequency of significant or life changing toxicity as perceived by patients. Incidence of life changing and significant toxicity was 15% and 24% respectively, which was associated with reduction in HRQoL across all tools. Conclusions: Here we describe the frequency of significant or life changing toxicity associated with ICI which will help clinicians in describing risk/benefit ratios to patients. Refining these tools facilitates more accurate future data collection in trials which better reflects the patient experience. irAE Life changing (LC) Significant short term (SST) Significant long term (SLT) Non-significant (NS) Grade 2n=281 17 (6%) 17 (6%) 10 (4%) 237 (84%) Grade 3n=122 14 (12%) 53 (43%) 9 (7%) 46 (38%) Grade 4n=8 2 (25%) 4 (50%) 1 (12.5%) 1 (12.5%)
Role of the platelet-lymphocyte ratio as a prognostic indicator in patients with intracranial hemorrhage: A systematic review and meta-analysis
Background The prognostic value of platelet-lymphocyte ratio (PLR) in ischemic stroke had been investigated in previous studies. However, the results of studies on PLR in patients with intracranial hemorrhage (ICH) are inconsistent. We aimed to conduct a meta-analysis to determine the prognostic value of PLR in predicting functional outcome and mortality in patients with ICH. Methods We searched the databases of PubMed, Embase, the Cochrane Library, and CNKI for relevant studies up to 10th June 2024. The Newcastle Ottawa Quality Assessment Scale (NOS) was applied to evaluate the quality of the included studies. We calculated the pooled odds ratios (OR) with 95% confidence intervals (CI) between PLR and both functional outcome (as measured by the modified Rankin Scale, mRS) as well as mortality. Poor functional outcomes were defined as mRS > 2. Results A total of 6 studies with 2992 patients were included. The random effects meta-analysis demonstrated that elevated PLR exhibited an association with poor functional outcome in patients with ICH (OR = 1.69; 95% CI [1.39–2.07]; P<0.0001; I2 = 24%). Similarly, elevated PLR was associated with mortality in patients with ICH (OR = 1.65; 95% CI [1.12–2.43]; P = 0.01; I2 = 31%). Conclusion This study suggested that elevated PLR was significantly associated with poor functional outcome (mRS>2) and increased mortality, indicating that elevated PLR could serve as a reliable a prognostic factor for unfavorable clinical outcomes in patients with ICH. It is advisable to conduct extensive prospective investigations across diverse ethnic backgrounds to verify the accuracy of this correlation prior to its utilization in clinical settings.
A prosperous and thorough analysis of gravity profiles for resources exploration utilizing the metaheuristic Bat Algorithm
Analysis of distinct genomic, transcriptomic, and immune landscapes driven by alterations in androgen production, uptake, and conversion (APUC) genes in metastatic prostate cancers.
209 Background: Prostate cancer (PC) progression is driven by aberrant activity of the androgen receptor (AR) or its associated ligands - androgens. Dysregulation of genes that regulate androgen production, uptake, and conversion (APUC) may impact the efficacy of hormone therapies for PC. In our recent study of primary (n=2593) or metastatic PC (n=4490) biopsies, 6 APUC genes ( HSD3B1 , HSD3B2 , CYP11A1 , CYP11B1 , CYP17A1 , CYP3A43 ) showed strong clustering in prostate adenocarcinoma. Tumors with high APUC expression (APUC-6 high) had low AR alterations/signaling activity and showed prolonged overall survival. Here we examined the genomic, transcriptomic, and immune cell-fraction compositions in APUC-6 high versus AR-high tumors. Given improved outcomes in APUC-6 high tumors, we hypothesize reduced features of tumor aggressiveness or a favorable immune milieu in these specimens. Methods: Metastatic PC samples in the SU2C/PCF dataset (n=208) were annotated as APUC-6 high or AR-high based on gene expression quartiles, with the upper quartile defining “high” status. Additional stratification was performed to ensure that no samples classified as both APUC-6 high and AR-high were included in either group. This stratified two groups of tumors (n= 41, each). Transcriptomic, genomic, and clinical features between the two groups were compared. Gene Set Enrichment Analysis was used to identify upregulated gene-expression hallmark pathways, and CIBERSORT was used to infer fractions of 22 immune cell types. Results: APUC-6 high tumors exhibited fewer AR genomic alterations, AR gene expression, and AR-V7 detection. APUC-6 high and AR-high groups harbored significant differences in mutation alteration frequencies of 4 genes: AR, EDN2, EDA2R, and OPHN1 (q < 0.05). There were no differences in the frequency of poor-prognosis mutations such as in TP53, PTEN, or RB1. APUC-6 high tumors were enriched in several hallmark inflammatory pathways and epithelial to mesenchymal transition (EMT) (NES>1.5, FDR<0.05). APUC-6 high tumors contained a higher fraction of naïve CD4 T-cells (224-fold, q = 0.0226), and also exhibited numerically higher levels of activated natural killer cells and neutrophils (1.35-fold and 2.11-fold, q = 0.081, 0.051, respectively), relative to AR-high tumors. Conclusions: APUC-6 high tumors, characterized by a favorable prognosis, are associated with upregulation of inflammatory pathways and EMT, and a distinct immune cell repertoire despite no difference in aberrations of canonical drivers of aggressiveness, such as TP53, PTEN , or RB1 status. The more inflamed tumor microenvironment observed in APUC-6 high tumors warrants further exploration of distinct clinical approaches to this distinct phenotype. Validation of these findings in larger cohorts is ongoing.
Detection of mutations in homologous recombination repair (HRR) pathway genes using liquid biopsy in metastatic, castration-resistant prostate cancer (mCRPC) patients without tumor tissue availability.
98 Background: Accurate detection of mutations in HRR pathway genes among patients with mCRPC is essential for selecting patients who would benefit with poly (ADP-ribsose) polymerase (PARP) inhibitor therapies. Traditional tissue-based detection methods can be associated with practical challenges as acquisition of specimens can involve significant risk or high costs. For prostate cancer patients, obtaining adequate tissue samples can be even more difficult, considering the unique characteristics of the disease. This study aimed to evaluate the real-world performance of liquid biopsy using circulating tumor DNA (ctDNA) in detecting mutations in HRR genes, among mCRPC patients who did not have tissue available for genomic evaluation. Methods: Blood samples (20ml of whole blood) were collected from 760 mCRPC patients in 10 Asian countries. Samples were collected once for each patient, regardless of treatment type or cycles as long as the patients were followed up for their mCRPC. All patients included were confirmed from each participating site to have no tissue available for genomic analysis. Blood samples were analyzed using a next-generation sequencing (NGS) based ctDNA assay, covering 15 genes in the HRR pathway ( ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L) . Results: ctDNA NGS testing was successfully performed in all 760 mCRPC patients. Any mutations in the HRR pathway genes were detected in 63.7% of the included patients and deleterious or suspected deleterious HRR pathway gene mutations were detected in 32.5% with the assay. Deleterious/suspected deleterious BRCA1/2 mutations were detected in 68/760 (8.95%) of the cases. Other detected deleterious/suspicious deleterious mutations included mutations in CDK12 , detected in 59/760 (7.76%) patients, followed by ATM mutation in 39/760 (5.13%), and CHEK2 in 31/769 (4.08%) by frequency. Conclusions: ctDNA testing for HRR gene mutations offers a practical tool for therapy selection in mCRPC patients. This non-invasive approach enables testing for patients who were not eligible for evaluation by tissue-based methods and can expand access to adequate targeted therapies.
Individual patient data (IPD) analysis of early PSA nadir in ARASENS, LATITUDE, and TITAN: Training and validation of a novel model.
192 Background: Early PSA nadir after systemic therapy in mHSPC is a predictor of overall survival. There are no prediction models that have been validated in randomized clinical trials (RCTs) to help identify patients who experience early PSA response. Using IPD from three phase III randomized trials, ARASENS, LATITUDE, and TITAN, we trained and validated a model to predict early PSA nadir in mHSPC patients. Methods: Eligible trials that randomized mHSPC patients to receive an androgen receptor pathway inhibitor (ARPI) were identified through Medline and clinicaltrials.gov. Three trials were identified that had available IPD through online data-sharing portals, and a pre-specified analysis plan was approved. Early PSA nadir was defined as ≤0.2 ng/mL by 6 months of random allocation. Patients who received androgen deprivation (ADT) (+/- docetaxel [doce]) with ARPI, were split randomly 60:40 into a training and a testing cohort. Patients who received ADT monotherapy (+/- doce) as standard of care (SOC) were used as a validation cohort. A random forest classifier model was constructed in the training cohort with 10-fold cross-validation. Included variables were age, performance status, body mass index (BMI), Gleason score, metastatic stage at diagnosis, visceral metastasis, PSA and hemoglobin at baseline, use of docetaxel, and receipt of prior local therapy (RP and/or RT). After internal validation in the testing cohort, the locked model was applied to the validation cohort, and performance was assessed with area under curve (AUC) and Brier score. Results: Data was available for 3434 patients. Overall, 1718 patients received SOC plus ARPI and 1716 patients received SOC alone. The training cohort consisted of 1030 patients while the testing cohort and validation cohort consisted of 688 and 1716 patients, respectively. The top 5 variables in order of importance were baseline PSA, hemoglobin, BMI, age, and ECOG performance status. The AUC for the testing and validation cohort was 0.75 and 0.77, respectively. When stratified by tertile of predicted probability, the proportion of PSA nadir was 32%, 52%, and 83% in the testing cohort and 7%, 15%, and 41% in the validation cohort, respectively. The Brier scores for the testing and validation cohort were 0.20 and 0.26, respectively. The modest calibration (i.e., higher Brier score) in the validation (SOC alone) cohort could be attributed to slight overprediction of early PSA nadir probability by a model trained in SOC plus ARPI group. Conclusions: To our knowledge, this is the first trained and validated model to predict early PSA nadir by 6 months of treatment initiation in mHSPC using data from multiple phase III RCTs. This model could provide clinical utility to guide treatment and monitoring strategies, as well as conducting clinical trials to enrich patient accrual for those clinically impacted by early PSA nadir.
Identifying children who develop severe chronic kidney disease using primary care records
Background Understanding whether symptoms suggestive of chronic kidney disease (CKD) are reported to primary care before diagnosis may provide opportunities for earlier detection, thus supporting strategies to prevent progression and improve long-term outcomes. Our aim was to determine whether symptoms/signs or consultation frequency recorded in primary care could predict a subsequent diagnosis of chronic kidney disease in children. Methods We undertook a case-control study within Clinical Practice Research Datalink. Cases were children <21 years with an incident code for severe CKD during the study period (January 2000-September 2018). Controls were matched on age (+/-3 years), sex, and practice-level kidney function testing rate. Conditional logistic regression modelling was used to identify symptoms predictive of severe CKD and differences in consultation frequency in 24- and 6-month timeframes before the index date. Results Symptoms predictive of severe CKD in the 24 months before the index date included growth concerns (OR 7.4, 95% CI 3.5, 15.4), oedema (OR 5.7, 95% CI 2.9, 11.2) and urinary tract infection (OR 3.3, 95% CI 2.1, 5.4); within 6 months of the index date, effect estimates and specificity strengthened although sensitivity decreased. Overall, positive predictive value of symptoms was low. Cases consulted more frequently than controls in both timeframes. In combination, symptoms and consultation frequency demonstrated modest discrimination for CKD (c-statistic after bootstrapping 0.70, 95% CI 0.66, 0.73). Conclusion Despite increased consultation frequency and several symptoms being associated with severe chronic kidney disease, the positive predictive value of symptoms is low given disease rarity making earlier diagnosis challenging.
Psychometric validation of the 20-item K-DOCS in Chinese adolescents: a multi-method approach
Difference in renal cell carcinoma (RCC) prevalence between kidney transplant versus other solid organ transplant patients.
520 Background: The annual incidence of renal cancer is 0.02% among the general United States population. End stage renal disease (ESRD) and exposure to dialysis are thought to be the primary drivers of increased risk of renal cancer in renal transplant patients rather than immunosuppression. This has been evidenced by how the incidence of RCC in heart transplant recipients is no different than the normal population. In this study, we aim to characterize RCC incidence among kidney transplant patients (usually exposed to ESRD/dialysis) versus other solid organ transplant patients (usually unexposed to ESRD/dialysis). Methods: We used CPT codes to search for patients who had received a solid organ transplant (kidney, liver, heart, lung, pancreas) at all Mayo Clinic sites from 1/1/2018 to 1/1/2024. Within this cohort, we identified those who had been diagnosed with kidney cancer after initiating dialysis or receiving a transplant, and retrospectively extracted data related to demographics, cancer diagnosis, and transplant details. Results: We identified 10873 patients who had received a solid organ transplant (Table 1). Of these, 178 (1.76%) were diagnosed with kidney cancer after either starting dialysis or receiving a transplant. These 178 patients were of median age 56 years at time of cancer diagnosis (STD 12), 71% male, 70% white, 20% black, 4.5% Asian, 2.8% American Native. Of 5792 patients who had received a kidney transplant (with or without another solid organ transplant), 172 (2.97%) were diagnosed with kidney cancer after having started dialysis or receiving a kidney transplant. Of these 172, 156 (91%) were exposed to dialysis (107 primarily hemodialysis and 48 peritoneal). Of 4392 patients who had received a solid organ transplant other than kidney (liver, heart, lung, and/or pancreas), 6 (0.14%) were diagnosed with kidney cancer after having received a kidney transplant. Of these 6, none underwent dialysis. Conclusions: Patients with kidney transplants are at increased risk of kidney cancer compared to patients with non-kidney solid organ transplants (2.97% vs 0.14%). This supports prior evidence showing ESRD plays a significant role in the pathogenesis of kidney cancer. Patients who received solid organ transplants at Mayo Clinic from 2018-2024 and were subsequently diagnosed with kidney cancer. n % With RCC after TXP 178 1.7587% Cancer Diagnosis after Kidney HD/TXP 172 2.9696% Cancer Diagnosis after Other TXP 6 0.1386% Patients who received solid organ transplants at Mayo Clinic from 2018-2024 n % Unique Patients 10121 100% Kidney Transplant 5792 57.23% Alone 5088 50.27% &Liver 332 3.28% &Heart 119 1.18% &Lung 8 0.08% &Pancreas 245 2.42% Non-kidney Transplant (Liver, Heart, Lung, or Pancreas) 4329 42.77% TXP: Transplant, HD: Hemodialysis.
Clinically advanced urothelial bladder cancer (CAUBC) in young onset bladder cancer (YOUC) patients: A genomic landscape study.
666 Background: CAUBC (any patients with node positive, metastasis positive or inoperable T4 disease) arising in YOUC is a challenging disease with significant need for improvements in systemic therapy especially for patients with surgically incurable disease. Methods: 9,411 cases of CAUBC underwent comprehensive genomic profiling (CGP) to examine all classes of genomic alterations (GA). MSI high status, tumor mutation burden (TMB) levels, genomic ancestry and trinucleotide mutational signatures were determined from the sequencing data. HRDsig status was calculated using a broad set of genome-wide copy number features (PMID 37769224). PD-L1 was determined by IHC using the Dako 22C3 tumor proportional score (TPS) system. Results were compared using the Fisher exact system with the Benjamini-Hochberg adjustment to correct for false discovery. Results: 291 (3.1%) CAUBC developed in YOUC patients under the age of 50 (CAUBC<50). The GA and biomarkers were compared with 9,120 CAUBC that developed in patients 50 years of age and older (CAUBC>50). The male gender preponderance in the CAUBC>50 was greater than in the CAUBC<50 cases (75.1% vs 69.4%; p=.069). The GA/tumor were higher in the CAUBC>50 (8.0 vs 7.0; p<.0001). Genomic ancestry distribution revealed significantly more Admixed American cases in the CAUBC<50 (8.9% vs 5.2%; P=.033) and more European cases in the CAUBC>50 (85.3% vs 74.9%; P<.0001). MSI high status was extremely uncommon (range 0.3% to 0.8%; NS). The frequency of TMB > 10 mutations/Mb was higher in the CAUBC>50 patients (35.1% vs 28.5%; P=.048). An APOBEC trinucleotide signature was more frequent in the CAUBC>50 patients (32.5% vs 25.8%; p=.041). PD-L1 low expression (1-49% TPS) was available in small subsets of cases and was similar in both groups (21.5% vs 28.5%; p=.84). GA in KMD6A (26.6% vs 14.8%; p=.0001), ERBB2 (18.4% vs 16.8%; p=.85.), ERBB3 (6.3% vs 6.5%; p=.91) MTAP (25.0% vs 20.3%; p=.27) and TERT (78.0% vs 68.4%; p=.005) were more frequent in CAUBC>50 cases and GA in HRAS (4.8% vs 2.1%; p=.11) and CCND1 (16.2% vs 13.1%; p=.35) were more frequent in the CAUBC<50 cases. GA in FGFR1 (4.1% vs 5.2%; p=.71), FGFR3 (14.1% vs 17.9%; p=.31), PIK3CA (20.3% vs 21.3%; p=.91) and PTEN (6.5% vs 4.5%; p=.31) were similar in both groups. Conclusions: In review of the CGP data, in contrast with CAUBC arising in older patients > 50 years of age, CAUBC arising in YOUC patients <50 years features a unique patten of biomarker and GA distribution that has potential to influence therapy selection and guide future clinical trials. CAUBC 0-49 years CAUBC >50 years P-value Sex (% male) 69.4% 75.1% .069 AMR ancestry 8.9% 5.2% .033 EUR ancestry 74.9% 85.3% <.0001 FGFR3 14.1% 17.9% NS KDM6A 14.8% 26.6% .0001 MTAP 20.3% 25.0% NS TERT 68.4% 78.0% .005 TMB>10 mut/Mb 28.5% 35.1% .048 APOBEC Signature 25.8% 32.5% .041
Differences in incidence and clinicopathologic features of secondary bladder cancer after long-term follow-up of brachytherapy and radical prostatectomy for localized prostate cancer.
381 Background: Although there studies have been reported that brachytherapy (BT) for prostate cancer is associated with an increased incidence of metachronous urinary bladder cancer (MBC), few studies have clarified differences in the clinicopathological features (CPF) of MBC between BT and prostatectomy (RP). We studied the risk and clinicopathological CPF of MBC between RP and BT groups in our hospital after long-term follow-up. Methods: Five hundred four patients treated with BT and 471 referred patients treated with RP between 2006 and 2017 in our hospital were reviewed. We compared the incidence of MBC and the CPF including the tumor number, location within the bladder, histology, and time from BT or RP to the MBC occurrence between BT and RP. The differences between the two groups were analyzed. Furthermore, in the BT group, the radiation dose distribution within bladder was estimated. Results: A total of 11 cases of MBC occurred in the BT group (2.2%) and 7 in the RP group (1.5%) after a median follow-up time of 107 months (13-209). The median time from initial treatments to the occurrences of MBC was 65 months (12-121) in BT and 100 months (4-126) in RP (p=0.469). Average tumor number was not significantly different between the groups (BT:1.4, RP:1.9, p=0.589). The tumor locations of MBC within the bladder for BT vs. RP were 9 vs. 1 in the lateral wall, 0 vs. 4 in the posterior wall, 0 vs. 3 in the dome, and 1 vs. 0 in the trigone. The incidence in the lateral wall was significantly higher in BT than in RP (p=0.001). Their median radiation dose of right wall (15.7±7.74Gy) and left wall (13.0±5.85Gy) showed no significant difference compared to the BT patients without MBC. There were 3 muscle-invasive cases in BT and 1 in RP (p=0.60). High-grade urothelial carcinoma occurred significantly more in BT (10 cases) than in RP (1 case) (p=0.001). According to the criteria, six MBC were judged as radiation-induced secondary bladder cancer. Conclusions: Long-term follow-up showed that the risk of MBC after BT was similar to that after RP. MBC after BT occurred significantly more frequently in the lateral wall and had a higher grade compared to those after RP.
Enhancing contact recommendation in social platforms through mental health awareness: Exploring Anorexia Nervosa as a case study
We analyze and propose a solution for the exposure of vulnerable users to harmful content during their interaction with contact recommender systems in social platforms. Our approach is dedicated to maximizing the number of harmless accounts suggested to users at risk. For these users, the over-personalization of recommender systems can result in an exposure to triggering content. We consider anorexia nervosa as a use case. People with anorexia tend to seek accounts of peers that support their unhealthy habits. Contact recommender systems can unintentionally reinforce such behaviors. Our approach modifies the objective function of a content and topology-based recommendation algorithm to maximize the suggestion of harmless accounts for users at risk. This is done with data from Twitter of Spanish speaking users with anorexia. The design and evaluation of the proposal has involved the participation of clinicians and volunteers at the last stages of treatment. Results show that users with anorexia are willing to follow harmless accounts suggested in online platforms. There is a tradeoff in precision (Pr) when comparing our proposal (Pr = 0.41) with a regular recommendation approach (Pr = 0.58). However, results are promising as there is a 55% increase in the percentage of harmless accounts suggested.